Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women

M. D'Amore, M. Fanelli, S. D'Amore, A. Fontana, G. Minenna

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim. Osteoporosis is a bone disease, characterized by a reduction of bone resistance; in postmenopausal period bone metabolism is unbalanced. Several parameters have been proposed as markers of bone metabolism; the attention have been recently placed on the receptor of activator of NF(Kappa)B ligand receptor (RANKL) and osteoprotegerin (OPG), namely RANKL/OPG system. The aim of this paper is to evaluate changes in postmenopausal women in serum concentration of OPG, RANKL, and their ratio (i.e. RANKL/OPG ratio), osteopontin (OPN), bone-type alcaline phosphatase (BAP), serum-N-Telopeptide of type I collagen (serum-NTX); and their correlations with bone mineral density (BMD). Methods. An Apulian population group of 163 native postmenopausal women were followed at the Osteoporosis Centre of Policlinico of Bari (Southenrn Italy). Patients were classified into 3 separate groups, according to T-score: osteoporotic, osteopenic and control group. Serum concentrations of OPG, RANKL, RANKL/OPG ratio, BAP and NTX have been calculated. Results. No differences were found in OPG and BAP values. Significant correlations were found in the osteopenic group between OPG and RANKL (negative), and between RANKL and OPN or serum-NTX, OPN and serum-NTX or RANKL/OPG ratio, BAP and serum-NTX, serum-NTX and RANKL/OPG ratio (positive). In the other groups a significant correlation was observed between BAP and NTX. Conclusions. In postmenopausal women, important modifications of bone metabolism markers (i.e. RANKL, OPG and OPN) could be due to serious engagement of bone turnover, especially in the pre-osteoporotic phase. Low bone density in postmenopausal women should be identified as soon as possible, and urgent measures are needed to reverse the process. Parameters namely RANKL e OPG may become an impor tant index for the evaluation of the activity of drugs against osteoporosis, old and new like AMG 162 (anti-RANKL action).

Original languageEnglish
Pages (from-to)215-221
Number of pages7
JournalPanminerva Medica
Volume48
Issue number4
Publication statusPublished - Dec 2006

Fingerprint

Receptor Activator of Nuclear Factor-kappa B
RANK Ligand
Osteopontin
Osteoprotegerin
Bone and Bones
Phosphoric Monoester Hydrolases
Serum
Population
Osteoporosis
Bone Density
Postmenopause
Drug Evaluation
Bone Remodeling
Bone Diseases
Collagen Type I
Population Groups
Italy

Keywords

  • NF(Kappa)B ligand
  • Osteopontin
  • Osteoporosis
  • Osteoprotegerin
  • Postmenopause

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. / D'Amore, M.; Fanelli, M.; D'Amore, S.; Fontana, A.; Minenna, G.

In: Panminerva Medica, Vol. 48, No. 4, 12.2006, p. 215-221.

Research output: Contribution to journalArticle

@article{c14965da42df4ae282b67521d8f16b0d,
title = "Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women",
abstract = "Aim. Osteoporosis is a bone disease, characterized by a reduction of bone resistance; in postmenopausal period bone metabolism is unbalanced. Several parameters have been proposed as markers of bone metabolism; the attention have been recently placed on the receptor of activator of NF(Kappa)B ligand receptor (RANKL) and osteoprotegerin (OPG), namely RANKL/OPG system. The aim of this paper is to evaluate changes in postmenopausal women in serum concentration of OPG, RANKL, and their ratio (i.e. RANKL/OPG ratio), osteopontin (OPN), bone-type alcaline phosphatase (BAP), serum-N-Telopeptide of type I collagen (serum-NTX); and their correlations with bone mineral density (BMD). Methods. An Apulian population group of 163 native postmenopausal women were followed at the Osteoporosis Centre of Policlinico of Bari (Southenrn Italy). Patients were classified into 3 separate groups, according to T-score: osteoporotic, osteopenic and control group. Serum concentrations of OPG, RANKL, RANKL/OPG ratio, BAP and NTX have been calculated. Results. No differences were found in OPG and BAP values. Significant correlations were found in the osteopenic group between OPG and RANKL (negative), and between RANKL and OPN or serum-NTX, OPN and serum-NTX or RANKL/OPG ratio, BAP and serum-NTX, serum-NTX and RANKL/OPG ratio (positive). In the other groups a significant correlation was observed between BAP and NTX. Conclusions. In postmenopausal women, important modifications of bone metabolism markers (i.e. RANKL, OPG and OPN) could be due to serious engagement of bone turnover, especially in the pre-osteoporotic phase. Low bone density in postmenopausal women should be identified as soon as possible, and urgent measures are needed to reverse the process. Parameters namely RANKL e OPG may become an impor tant index for the evaluation of the activity of drugs against osteoporosis, old and new like AMG 162 (anti-RANKL action).",
keywords = "NF(Kappa)B ligand, Osteopontin, Osteoporosis, Osteoprotegerin, Postmenopause",
author = "M. D'Amore and M. Fanelli and S. D'Amore and A. Fontana and G. Minenna",
year = "2006",
month = "12",
language = "English",
volume = "48",
pages = "215--221",
journal = "Panminerva Medica",
issn = "0031-0808",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women

AU - D'Amore, M.

AU - Fanelli, M.

AU - D'Amore, S.

AU - Fontana, A.

AU - Minenna, G.

PY - 2006/12

Y1 - 2006/12

N2 - Aim. Osteoporosis is a bone disease, characterized by a reduction of bone resistance; in postmenopausal period bone metabolism is unbalanced. Several parameters have been proposed as markers of bone metabolism; the attention have been recently placed on the receptor of activator of NF(Kappa)B ligand receptor (RANKL) and osteoprotegerin (OPG), namely RANKL/OPG system. The aim of this paper is to evaluate changes in postmenopausal women in serum concentration of OPG, RANKL, and their ratio (i.e. RANKL/OPG ratio), osteopontin (OPN), bone-type alcaline phosphatase (BAP), serum-N-Telopeptide of type I collagen (serum-NTX); and their correlations with bone mineral density (BMD). Methods. An Apulian population group of 163 native postmenopausal women were followed at the Osteoporosis Centre of Policlinico of Bari (Southenrn Italy). Patients were classified into 3 separate groups, according to T-score: osteoporotic, osteopenic and control group. Serum concentrations of OPG, RANKL, RANKL/OPG ratio, BAP and NTX have been calculated. Results. No differences were found in OPG and BAP values. Significant correlations were found in the osteopenic group between OPG and RANKL (negative), and between RANKL and OPN or serum-NTX, OPN and serum-NTX or RANKL/OPG ratio, BAP and serum-NTX, serum-NTX and RANKL/OPG ratio (positive). In the other groups a significant correlation was observed between BAP and NTX. Conclusions. In postmenopausal women, important modifications of bone metabolism markers (i.e. RANKL, OPG and OPN) could be due to serious engagement of bone turnover, especially in the pre-osteoporotic phase. Low bone density in postmenopausal women should be identified as soon as possible, and urgent measures are needed to reverse the process. Parameters namely RANKL e OPG may become an impor tant index for the evaluation of the activity of drugs against osteoporosis, old and new like AMG 162 (anti-RANKL action).

AB - Aim. Osteoporosis is a bone disease, characterized by a reduction of bone resistance; in postmenopausal period bone metabolism is unbalanced. Several parameters have been proposed as markers of bone metabolism; the attention have been recently placed on the receptor of activator of NF(Kappa)B ligand receptor (RANKL) and osteoprotegerin (OPG), namely RANKL/OPG system. The aim of this paper is to evaluate changes in postmenopausal women in serum concentration of OPG, RANKL, and their ratio (i.e. RANKL/OPG ratio), osteopontin (OPN), bone-type alcaline phosphatase (BAP), serum-N-Telopeptide of type I collagen (serum-NTX); and their correlations with bone mineral density (BMD). Methods. An Apulian population group of 163 native postmenopausal women were followed at the Osteoporosis Centre of Policlinico of Bari (Southenrn Italy). Patients were classified into 3 separate groups, according to T-score: osteoporotic, osteopenic and control group. Serum concentrations of OPG, RANKL, RANKL/OPG ratio, BAP and NTX have been calculated. Results. No differences were found in OPG and BAP values. Significant correlations were found in the osteopenic group between OPG and RANKL (negative), and between RANKL and OPN or serum-NTX, OPN and serum-NTX or RANKL/OPG ratio, BAP and serum-NTX, serum-NTX and RANKL/OPG ratio (positive). In the other groups a significant correlation was observed between BAP and NTX. Conclusions. In postmenopausal women, important modifications of bone metabolism markers (i.e. RANKL, OPG and OPN) could be due to serious engagement of bone turnover, especially in the pre-osteoporotic phase. Low bone density in postmenopausal women should be identified as soon as possible, and urgent measures are needed to reverse the process. Parameters namely RANKL e OPG may become an impor tant index for the evaluation of the activity of drugs against osteoporosis, old and new like AMG 162 (anti-RANKL action).

KW - NF(Kappa)B ligand

KW - Osteopontin

KW - Osteoporosis

KW - Osteoprotegerin

KW - Postmenopause

UR - http://www.scopus.com/inward/record.url?scp=33847652227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847652227&partnerID=8YFLogxK

M3 - Article

C2 - 17215793

AN - SCOPUS:33847652227

VL - 48

SP - 215

EP - 221

JO - Panminerva Medica

JF - Panminerva Medica

SN - 0031-0808

IS - 4

ER -